Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jun;14(6):774-781.
doi: 10.1111/jdi.14000. Epub 2023 Mar 5.

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Takahiro Iijima  1   2 , Makoto Shibuya  2 , Yuzuru Ito  3 , Yasuo Terauchi  1
Affiliations
Randomized Controlled Trial

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Takahiro Iijima et al. J Diabetes Investig. 2023 Jun.

Erratum in

Abstract

Introduction: Few studies have examined the effects of glucagon-like peptide-1 receptor agonist switching, particularly in Japanese patients. Therefore, we aimed to investigate the effects of switching from liraglutide to semaglutide or dulaglutide on blood glucose, body weight, and the occurrence of adverse effects in clinical practice.

Materials and methods: This was an open-label, prospective, randomized, parallel-group controlled trial. Patients with type 2 diabetes treated with liraglutide (0.6 or 0.9 mg) at Yokosuka Kyosai Hospital in Japan were recruited from September 2020 to March 2022 and, after obtaining informed consent, randomly assigned to the semaglutide or dulaglutide group (1:1). Changes in the glycated hemoglobin level from baseline to weeks 8, 16, and 26 were evaluated post-treatment.

Results: Initially, 32 participants were enrolled, of whom 30 completed the study. Glycemic control was significantly better in the semaglutide group than in the dulaglutide group (-0.42 ± 0.49% vs -0.00 ± 0.34%, P = 0.0120). Body weight significantly decreased in the semaglutide group (-2.6 ± 3.6 kg, P = 0.0153), whereas no change was observed in the dulaglutide group (-0.1 ± 2.7 kg, P = 0.8432). We found a significant difference in body weight between the groups (P = 0.0469). The proportion of participants who reported adverse events was 75.0% and 18.8% in the semaglutide and dulaglutide groups, respectively. One patient in the semaglutide group had difficulty continuing treatment due to severe vomiting and weight loss.

Conclusions: Switching from once-daily liraglutide to once-weekly semaglutide 0.5 mg significantly improved glycemic control and body weight compared with switching to once-weekly dulaglutide 0.75 mg.

Keywords: Diabetes mellitus; Dulaglutide; Semaglutide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of patient selection and management in the study.
Figure 2
Figure 2
Changes in HbA1c and BW. # P < 0.05, ## P < 0.01. BW, body weight; HbA1c, glycated hemoglobin.
See this image and copyright information in PMC

References

    1. Trujillo JM, Nuffer W, Ellis SL. GLP‐1 receptor agonists: a review of head‐to‐head clinical studies. Ther Adv Endocrinol Metab 2015; 6: 19–28. - PMC - PubMed
    1. Drucker DJ. The cardiovascular biology of glucagon‐like peptide‐1. Cell Metab 2016; 24: 15–30. - PubMed
    1. Burcelin R, Gourdy P. Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev 2017; 18: 86–98. - PubMed
    1. Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322. - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844. - PubMed

Publication types